These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916 [TBL] [Abstract][Full Text] [Related]
9. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
10. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Barale C; Bonomo K; Frascaroli C; Morotti A; Guerrasio A; Cavalot F; Russo I Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):282-291. PubMed ID: 31653513 [TBL] [Abstract][Full Text] [Related]
12. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia. White CM J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study. Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549 [TBL] [Abstract][Full Text] [Related]
14. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
15. PCSK9 in cholesterol metabolism: from bench to bedside. Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529 [TBL] [Abstract][Full Text] [Related]
16. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
17. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. Wang Y; Liu ZP Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249 [TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
20. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia. Schmitz J; Gouni-Berthold I Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]